Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11327-11334

  Brest, Patrick ^a   Gustafsson, Mattias ^a   Mossberg, Ann Kristin ^a   Gustafsson, Lotta ^a   Duringer, Caroline ^b   Hamiche, Ali ^c   Svanborg, Catharina ^a  

^a LUND UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c INSTITUT ANDRÉ LWOFF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA LACTALBUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA FRAGMENT; HISTONE; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL VIABILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CHROMATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INHIBITORS; FLOW CYTOMETRY; HELA CELLS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; JURKAT CELLS; LACTALBUMIN; OLEIC ACIDS;

EID: 37049000403     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1153     Document Type: Article

References (40)

1. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
2. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
3. Butler LM, Liapis V, Bouralexis S, et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006;119:944-54.
4. Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005;11:6382-9.
5. Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004;103:4636-43.
6. Mok KH, Pettersson J, Orrenius S, Svanborg C. HAMLET, protein folding, and tumor cell death. Biochem Biophys Res Commun 2007;354:1-7.
7. Pettersson J, Mossberg AK, Svanborg C. α-Lactalbumin species variation, HAMLET formation, and tumor cell death. Biochem Biophys Res Commun 2006;345:260-70.
8. Svensson M, Hakansson A, Mossberg AK, Linse S, Svanborg C. Conversion of α-lactalbumin to a protein inducing apoptosis. Proc Natl Acad Sci U S A 2000;97:4221-6.
9. Hakansson A, Zhivotovsky B, Orrenius S, Sabharwal H, Svanborg C. Apoptosis induced by a human milk protein. Proc Natl Acad Sci U S A 1995;92:8064-8.
10. Fischer W, Gustafsson L, Mossberg AK, et al. Human α-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res 2004;64:2105-12.
11. Gustafsson L, Leijonhufvud I, Aronsson A, Mossberg AK, Svanborg C. Treatment of skin papillomas with topical α-lactalbumin-oleic acid. N Engl J Med 2004;350:2663-72.
12. Hallgren O, Gustafsson L, Irjala H, et al. HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53. Apoptosis 2006;11:221-33.
13. Mossberg AK, Wullt B, Gustafsson L, et al. Bladder cancers respond to intravesical instillation of (HAMLET human α-lactalbumin made lethal to tumor cells). Int J Cancer 2007;121:1352-9.
14. Duringer C, Hamiche A, Gustafsson L, Kimura H, Svanborg C. HAMLET interacts with histones and chromatin in tumor cell nuclei. J Biol Chem 2003;278:42131-5.
15. Hamiche A, Kang JG, Dennis C, Xiao H, Wu C. Histone tails modulate nucleosome mobility and regulate ATP-dependent nucleosome sliding by NURF. Proc Natl Acad Sci U S A 2001;98:14316-21.
16. Simpson RT, Stafford DW. Structural features of a phased nucleosome core particle. Proc Natl Acad Sci U S A 1983;80:51-5.
17. Simpson RT, Thoma F, Brubaker JM. Chromatin reconstituted from tandemly repeated cloned DNA fragments and core histones: a model system for study of higher order structure. Cell 1985;42:799-808.
18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
19. Kangas L, Gronroos M, Nieminen AL. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 1984;62:338-43.
20. Gorisch SM, Wachsmuth M, Toth KF, Lichter P, Rippe K. Histone acetylation increases chromatin accessibility. J Cell Sci 2005;118:5825-34.
21. Paull TT, Rogakou EP, Yamazaki V, et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
22. Zhivotovsky B, Nicotera P, Bellomo G, Hanson K, Orrenius S. Ca2+ and endonuclease activation in radiation-induced lymphoid cell death. Exp Cell Res 1993;207:163-70.
23. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
24. Massague J. G1 cell-cycle control and cancer. Nature 2004;432:298-306.
25. Blagosklonny MV, Robey R, Sackett DL, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002;1:937-41.
26. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004;65:571-81.
27. Fotedar R, Bendjennat M, Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle 2004;3:134-7.
28. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97:10014-9.
29. Toth KF, Knoch TA, Wachsmuth M, et al. Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. J Cell Sci 2004;117:4277-87.
30. Ou JN, Torrisani J, Unterberger A, et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007;73:1297-307.
31. Gaymes TJ, Padua RA, Pla M, et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 2006;4:563-73.
32. Rosato RR, Almenara JA, Cartee L, et al. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol Cancer Ther 2002;1:253-66.
33. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
34. Gartel AL. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res 2005;29:1237-8.
35. Kondo S, Barna BP, Kondo Y, et al. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996;13:1279-85.
36. Lincet H, Poulain L, Remy JS, et al. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 2000;161:17-26.
37. Asada M, Yamada T, Ichijo H, et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999;18:1223-34.
38. Zhang Y, Fujita N, Tsuruo T. p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int J Cancer 1999;83:790-7.
39. Park JA, Kim KW, Kim SI, Lee SK. Caspase 3 specifically cleaves p21WAF1/CIP1 in the earlier stage of apoptosis in SK-HEP-1 human hepatoma cells. Eur J Biochem 1998;257:242-8.
40. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.